^
    Back
    Association details:
    Biomarker:HRAS mutation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Biomarkers in Patients With Head and Neck Cancer

    Excerpt:
    ...Mutation rates of HRAS and PIK3CA...
    Trial ID:
    NCT01466257
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Biol Med
    Title:

    Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer

    Published date:
    04/17/2020
    Excerpt:
    ...KRAS/HRAS mutations were associated with poor PFS among HNSCC patients treated with cetuximab...Hot spot activating PIK3CA and RAS mutations predicted cetuximab resistance among HNSCC patients…
    DOI:
    10.20892/j.issn.2095-3941.2019.0153